BridgeBio Pharma Inc.
BridgeBio Pharma Announces Royalty Interest Sale for $300M
Summary
On June 27, 2025, BridgeBio Pharma, Inc., through its subsidiary Eidos Therapeutics, Inc., sold certain royalty interests on acoramidis products to Acoramidis Royalty SPV, LP and LSI Financing Fund, LP for $300 million. The purchased royalty payments are subject to certain caps and conditions. The sale creates a direct financial obligation for BridgeBio under the terms of the Purchase Agreement.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement